Investor Presentaiton
Financial Ratios
SUN
PHARMA
FY14
FY15
FY16
FY17
FY18
Growth (%)
Sales
42.4
70.2
2.4
8.5
(13.9)
Gross Profit
44.4
55.1
5.1
2.7
(15.8)
EBITDA
45.0
8.5
(2.1)
16.1
(40.9)
Net Profit
5.3
44.5
0.1
53.2
(69.0)
Net Profit (Adjusted)
58.7 #
(15.6) #
9.5#
33.1
(51.7)#
Margins (%)
Gross Margin
82.6
75.3
77.3
73.1
71.5
EBITDA Margin (%)
44.5
28.3
27.1
29.0
19.9
Net Margin
19.6
16.7
16.3
23.0
8.3
Net Margin (Adjusted)
35.4 #
17.5 #
18.8 #
23.0
12.9 #
Return (%)
ROCE
ROE
Others
Debt/Equity
Fully Diluted (USD) EPS
26.9
14.3
14.6
16.1
7.8
30.9
18.5
17.6
19.8
8.9
0.13
0.27
0.25
0.22
0.26
15.2
18.9
18.9
28.9
9.0
Fully Diluted EPS (USD) (Adjusted)
R&D Spend % of Net Sales
27.3
#
19.9 #
21.7 #
28.9
14.0 #
6.5
7.2
8.3
7.6
8.6
Revenue
Capital
6.2
6.7
8.0
7.1
7.9
0.3
0.4
0.3
0.6
0.7
# # Adjusted for Rs 25.17 bn provision related to generic Protonix settlement for the year FY14 and
adjusted for Rs 2.4 bn for settlement provision for Texas Medicaid Program litigation for FY15 and
adjusted for Rs 6.9 bn of exceptional items related to Ranbaxy integration for FY16 and
adjusted for Rs 12.1 bn provision related to Modafinil settlement & deferred tax adjustment for the
FY18.
year
© Sun Pharmaceutical Industries Limited. All Rights Reserved.
49View entire presentation